Literature DB >> 2155284

Localization of antigenic sites of the E2 glycoprotein of transmissible gastroenteritis coronavirus.

I Correa1, F Gebauer, M J Bullido, C Suñé, M F Baay, K A Zwaagstra, W P Posthumus, J A Lenstra, L Enjuanes.   

Abstract

Four antigenic sites of the E2 glycoprotein of transmissible gastroenteritis virus were defined by competitive radioimmunoassays of monoclonal antibodies (MAbs). Here, we describe the localization of these sites by testing the antigenicity of protein fragments and prokaryotic expression products of E2 gene fragments, and by sequencing of MAb-resistant (mar) mutants. Partial proteolysis of purified E2 protein allowed the isolation of a 28K fragment recognized by both site A- and site C-specific MAbs. An antiserum against this fragment bound to a synthetic peptide containing residues 1 to 18 and to an expression product containing residues 1 to 325. The same expression product was recognized by site C-specific MAbs. These data indicate that residues within the sequence 1 to 325 contribute to site C and possibly also to site A. Sequencing of mar mutants that escaped neutralization by site A-specific MAbs indicated that residues 538 and 543 also belong to site A. The binding of site-specific MAbs to expression products led directly to the localization of sites B and D, between residues 1 to 325 and 379 to 529, respectively. The first 37% of the polypeptide chain of E2 appears to be more immunogenic than the rest of the sequence.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155284     DOI: 10.1099/0022-1317-71-2-271

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  37 in total

1.  The membrane M protein carboxy terminus binds to transmissible gastroenteritis coronavirus core and contributes to core stability.

Authors:  D Escors; J Ortego; H Laude; L Enjuanes
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Analysis and simulation of a neutralizing epitope of transmissible gastroenteritis virus.

Authors:  W P Posthumus; J A Lenstra; W M Schaaper; A P van Nieuwstadt; L Enjuanes; R H Meloen
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

3.  Analysis of murine coronavirus surface glycoprotein functions by using monoclonal antibodies.

Authors:  E Routledge; R Stauber; M Pfleiderer; S G Siddell
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

4.  Transgenic mice secreting coronavirus neutralizing antibodies into the milk.

Authors:  I Sola; J Castilla; B Pintado; J M Sánchez-Morgado; C B Whitelaw; A J Clark; L Enjuanes
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

5.  Processing and antigenicity of entire and anchor-free spike glycoprotein S of coronavirus TGEV expressed by recombinant baculovirus.

Authors:  M Godet; D Rasschaert; H Laude
Journal:  Virology       Date:  1991-12       Impact factor: 3.616

6.  Organization of two transmissible gastroenteritis coronavirus membrane protein topologies within the virion and core.

Authors:  D Escors; E Camafeita; J Ortego; H Laude; L Enjuanes
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

7.  Interference of coronavirus infection by expression of immunoglobulin G (IgG) or IgA virus-neutralizing antibodies.

Authors:  J Castilla; I Sola; L Enjuanes
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

8.  Localization of antigenic sites of the S glycoprotein of feline infectious peritonitis virus involved in neutralization and antibody-dependent enhancement.

Authors:  W V Corapi; R J Darteil; J C Audonnet; G E Chappuis
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

9.  Epitope specificity of protective lactogenic immunity against swine transmissible gastroenteritis virus.

Authors:  M De Diego; M D Laviada; L Enjuanes; J M Escribano
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

10.  Immunogenicity of the S protein of transmissible gastroenteritis virus expressed in baculovirus.

Authors:  T Tuboly; E Nagy; J R Dennis; J B Derbyshire
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.